A 2026 genetic study found that people with genetically higher levels of FGF-23, a blood protein, had an 8.2% increased risk of calcium buildup in their abdominal aorta. According to Gram Research analysis, phosphate, a mineral in the blood, may partially explain this connection, accounting for about 30% of the effect. However, this is early research showing association rather than proof of cause and effect.
Researchers used genetic analysis to study whether a protein called FGF-23 increases the risk of calcium buildup in the abdominal aorta, the major blood vessel in your belly. According to Gram Research analysis, they found that people with genetically higher FGF-23 levels had a modestly increased risk of this dangerous calcium accumulation. The study suggests that phosphate, a mineral in your blood, may explain part of this connection. While the findings are promising, they come from genetic studies that show association rather than direct proof of cause and effect.
Key Statistics
A 2026 genetic study published in Medicine found that genetically predicted higher FGF-23 levels were associated with an 8.2% increased risk of abdominal aortic calcification compared to lower levels.
According to the 2026 research, serum phosphate may partially mediate the association between FGF-23 and abdominal aortic calcification, accounting for approximately 30% of the total effect.
The 2026 Mendelian randomization study showed that after adjusting for phosphate levels, the association between FGF-23 and abdominal aortic calcification was no longer statistically significant, suggesting phosphate is a key link in the connection.
The Quick Take
- What they studied: Whether a blood protein called FGF-23 causes calcium to build up in the main artery in your abdomen, and whether phosphate levels explain this connection.
- Who participated: This was a genetic study using data from large databases of human genetic information. No specific patient group was directly studied; instead, researchers analyzed genetic patterns across many people.
- Key finding: People with genetically higher FGF-23 levels had about an 8% increased risk of abdominal aortic calcification. This association became weaker when phosphate levels were considered, suggesting phosphate plays a role in the connection.
- What it means for you: If confirmed by future research, monitoring FGF-23 and phosphate levels might help identify people at higher risk for dangerous calcium buildup in their arteries. However, this is early-stage research, and you should not change your health decisions based on this study alone.
The Research Details
This study used a method called Mendelian randomization, which is a special genetic technique that helps researchers figure out whether one thing actually causes another. Instead of following people over time, researchers looked at genetic variations that naturally occur in people’s DNA. These genetic variations act like a natural experiment that helps determine cause and effect.
The researchers examined genetic data to predict FGF-23 levels and then looked at whether people with genetically higher FGF-23 also had more calcium buildup in their abdominal aorta. They also tested whether phosphate, a mineral in the blood, might explain the connection between FGF-23 and calcium buildup. This is like checking whether FGF-23 works by changing phosphate levels, which then causes the calcium problem.
Genetic studies like this are valuable because they can suggest cause-and-effect relationships without waiting years for results. Regular studies following people over time are expensive and slow. However, genetic studies show associations that still need to be confirmed with other types of research. This approach helps scientists narrow down which factors are worth studying more carefully.
This study has several strengths: it used a rigorous genetic method, tested the association multiple ways, and adjusted for other factors that might affect the results. However, the study has limitations. The association was modest in size, meaning FGF-23 is just one of many factors affecting calcium buildup. The study cannot prove cause and effect, only suggest a connection. The findings need confirmation from other research before doctors would use them to guide treatment decisions.
What the Results Show
The main finding was that people with genetically predicted higher FGF-23 levels had an 8.2% increased risk of calcium buildup in the abdominal aorta compared to people with lower FGF-23 levels. This association held up even after researchers adjusted for other factors like calcium levels, vitamin D, and parathyroid hormone.
However, when researchers specifically accounted for phosphate levels, the association weakened significantly and was no longer statistically significant. This suggests that phosphate may be an important link in the chain connecting FGF-23 to calcium buildup. The mediation analysis indicated that phosphate might explain about 30% of the total effect of FGF-23 on calcium accumulation.
These results suggest that FGF-23 may increase calcium buildup in arteries partly by raising phosphate levels. The findings are consistent with what scientists already know about how these substances interact in the body.
The study tested the association in multiple ways to check if the results were reliable. When researchers used a different genetic database for FGF-23, the results remained directionally consistent but became weaker after adjusting for phosphate. This consistency across different analyses strengthens confidence in the findings, though it also shows the effect is modest rather than dramatic.
Previous research has shown that FGF-23 is involved in controlling phosphate levels in the body and that high phosphate is linked to calcium buildup in arteries. This study connects those two pieces of information by suggesting FGF-23 may increase artery calcification through its effects on phosphate. The findings fit with existing knowledge about how these substances work together in the body.
This study has important limitations. First, it shows association based on genetics, not direct cause and effect. Second, the effect size is modest, meaning FGF-23 is just one factor among many affecting calcium buildup. Third, the study used genetic data rather than measuring actual FGF-23 and phosphate levels in patients. Fourth, the mediation effect of phosphate was only marginally significant statistically. Finally, the study cannot explain why some people with high FGF-23 develop calcium buildup while others do not.
The Bottom Line
Based on this research, there are no immediate changes to make in your daily life. The findings are suggestive but not yet strong enough to guide clinical decisions. If you have risk factors for heart disease or calcium buildup in arteries, continue following your doctor’s recommendations about diet, exercise, and medications. Future research may eventually lead to new screening or treatment approaches based on FGF-23 and phosphate levels.
This research is most relevant to cardiologists and kidney specialists who treat patients at risk for vascular calcification. People with chronic kidney disease should be aware of this research since kidney disease affects both FGF-23 and phosphate levels. People with a family history of early heart disease or calcium buildup in arteries may find this research interesting. However, this is not yet actionable information for the general public.
This is early-stage research. If the findings are confirmed by other studies, it may take 5 to 10 years before doctors could use FGF-23 or phosphate testing to identify high-risk patients. Any new treatments based on these findings would take even longer to develop and test.
Frequently Asked Questions
What is FGF-23 and why does it matter for my heart health?
FGF-23 is a protein that helps control phosphate levels in your blood. A 2026 study found that genetically higher FGF-23 levels are associated with increased calcium buildup in the abdominal aorta, your body’s main artery. This connection may work through phosphate levels.
Does high FGF-23 mean I will definitely get calcium buildup in my arteries?
No. The 2026 study found only a modest 8.2% increased risk associated with higher FGF-23 levels. Many other factors affect whether calcium builds up in arteries. This research shows association, not that FGF-23 directly causes the problem in every person.
Should I ask my doctor to test my FGF-23 levels?
Not yet based on this single study. FGF-23 testing is not standard for most people. If you have chronic kidney disease or heart disease risk factors, discuss with your doctor whether any new testing might help your care. This research is too early to guide routine screening.
How can I reduce my phosphate levels to protect my arteries?
Limit processed foods, cured meats, dairy products, and nuts, which are high in phosphate. Drink less soda and avoid phosphate additives in packaged foods. If you have kidney disease, ask your doctor or dietitian for personalized phosphate reduction strategies.
When will doctors use this research to treat patients?
This is early-stage research. If confirmed by other studies, it may take 5 to 10 years before doctors could use FGF-23 testing to identify high-risk patients. Any new treatments would take even longer to develop and prove safe and effective.
Want to Apply This Research?
- If your doctor has measured your phosphate levels, track them over time in your health app. Note the date, value, and any dietary changes you made. This creates a personal record you can discuss with your healthcare provider.
- If you have kidney disease or high phosphate levels, work with a dietitian to reduce phosphate-rich foods like processed meats, dairy, and nuts. Log your dietary choices in your app to monitor whether changes affect your phosphate levels at your next blood test.
- Set reminders for regular blood work if your doctor recommends monitoring phosphate levels. Track results over months and years to see trends. Share this data with your healthcare provider to make informed decisions about your heart and kidney health.
This research is preliminary and shows genetic association, not proven cause and effect. The findings should not be used to make changes to your diet, supplements, or medications without consulting your doctor. If you have chronic kidney disease, heart disease, or concerns about calcium buildup in your arteries, discuss this research with your healthcare provider. This article is for educational purposes and does not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.